Feb 4 (Reuters) - AbbVie forecast 2026 profit above Wall Street estimates on Wednesday after posting a fourth-quarter results ...

AbbVie (NYSE:ABBV) has agreed to acquire Capstan Therapeutics to expand its work in in vivo CAR-T cell therapy. The company ...

AbbVie on Tuesday said the applications with the U.S. Food and Drug Administration and the European Medicines Agency cover Rinvoq for the treatment of adults and adolescents with non-segmental ...

Year Diluted EPS of $2.36 on a GAAP Basis, a Decrease of 1.3 Percent; Adjusted Diluted EPS of $10.00, a Decrease of 1.2 Percent; These Results Include an Unfavorable ...

AbbVie is projected to guide 2026 in line with estimates but is likely to raise long-term guidance on Skyrizi/Rinvoq. Over the last 2 years, ABBV has beaten EPS estimates 63% of the time and has ...

AbbVie is scheduled to report fourth-quarter results before the market opens Wednesday. Here is what you need to know. NET INCOME: The biopharmaceutical conglomerate is projected to post a profit of ...